Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04642820 · ClinicalTrials.gov registry record · Early Phase 1
Drugs Brain and Behavior (DDP)
A Early Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 138
- Enrollment target
NCT04642820 is a Early Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 138 participants.
The verdict
NCT04642820, a Early Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 138 participants
- Enrollment target
Study Summary
In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
Interventions
- DRUG Methamphetamine
- DRUG placebo oral tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2024-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04642820
The ClinicalTrials.gov registry entry for NCT04642820 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Methamphetamine is the first listed.
NCT04642820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04642820 about?
NCT04642820 is a clinical study titled "Drugs Brain and Behavior (DDP)". In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.
What is the current status of trial NCT04642820?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 138 participants. The study started on 2020-11-01. Estimated completion is 2024-06-01.
What interventions are being tested in trial NCT04642820?
The interventions under investigation include: Methamphetamine (DRUG), placebo oral tablet (DRUG).
Who is sponsoring clinical trial NCT04642820?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.